Final Results

AI SummaryClose X

SkinBioTherapeutics plc reported a significant increase in revenue to £4.6 million for the year ended June 30, 2025, up 284% from £1.2 million in the prior year, driven by contributions from AxisBiotix™ direct sales, Dermatonics, and Bio-Tech Solutions, alongside royalty income. The company reduced its adjusted EBITDA loss to £0.4 million from £2.1 million and improved its operating loss by 61% to £1.1 million. Cash and cash equivalents stood at £4.8 million, bolstered by successful fundraising efforts totaling £5.76 million. Key operational developments include the finalization of a commercial agreement with Croda for SkinBiotix® (Zenakine™) and the launch of AxisBiotix™ products in over 180 Superdrug stores. The company anticipates FY26 revenue of £6.2 million and adjusted EBITDA of £0.7 million.

Disclaimer*

UK 100

Latest directors dealings